MorphoSys Foresees 10 New Program Starts In 2014, Earnings Deficit
This article was originally published in The Pink Sheet Daily
MorphoSys expects both partnered and proprietary activities to generate around 10 new program starts this year as the German biotech strongly boosts its R&D investment, a plan that will generate its first earnings shortfall in a decade.
You may also be interested in...
Merck beats out bids from AbbVie and Johnson & Johnson for Idenix Pharmaceuticals, gaining possession of three promising HCV drug candidates.
Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.